Akari Therapeutics (AKTX) dropped some intriguing preclinical data on Tuesday for its experimental cancer drug, AKTX-101. The headline: it works in scenarios where current antibody-drug conjugates (ADCs) fall short, particularly in urothelial cancer. That's a big deal because while ADCs have been a bright spot in oncology, they're not perfect, and patients who relapse after standard treatments often run out of options.
AKTX-101 is a TROP2-directed ADC, but here's the twist: it uses a proprietary PH1 RNA spliceosome-modulating payload. Instead of relying on the usual payload categories like topoisomerase 1 inhibitors or microtubule inhibitors, this one messes with RNA splicing. That's a different angle, and it might just be the key to outsmarting resistance.
Urothelial carcinoma, the most common type of bladder cancer, is a hot market for ADCs right now. Drugs like Padcev have been game-changers, but they're not a cure-all. When patients relapse, the options get thin. Akari's approach could fill that gap.
In the lab, AKTX-101 showed meaningful anti-tumor activity across several clinically relevant models. In one model of advanced urothelial carcinoma (UM-UC-14), which mimics a metastatic setting where Padcev is typically the first-line treatment, AKTX-101 achieved statistically significant tumor growth inhibition. Padcev, meanwhile, showed limited effectiveness in that same model. That's a strong signal.
Even more compelling: AKTX-101 also worked against tumors that had developed resistance to Trodelvy, a first-generation TROP2-directed ADC. When those resistant tumors were treated with AKTX-101, their growth slowed significantly. The company believes the PH1 payload's ability to disrupt RNA splicing can overcome resistance linked to traditional Topoisomerase I payloads. That could have implications beyond urothelial cancer, potentially extending to lung and breast cancers.
So what's next? Akari is pushing forward with IND-enabling processes for AKTX-101. The goal is to launch a Phase 1 clinical trial by mid-2027. In the meantime, they're also exploring other uses for the PH1 payload platform to maximize its commercial potential.
Investors seem cautiously optimistic. Akari's stock was up 2.26% to $7.79 at the time of publication on Tuesday.
It's early days, and preclinical data doesn't always translate to clinical success. But for a company with a differentiated approach in a space where resistance is a growing problem, this is a promising step. Keep an eye on Akari as it moves toward the clinic.
